Footnotes ↵∗Drs. Myhre and Vaduganathan contributed equally to this work as co-first authors.The PARADIGM-HF trial was funded by Novartis AG. Dr. Myhre has received speaker fees from Novartis; and is supported by a post...
【关键词】 PARADIGM-HF 试验; 慢性射血分数降低心力衰竭; 血管紧张素受体和脑啡 肽酶双重抑制剂 PARADIGM-HF trial and its important clinical significance Liu Jinlai. Department of Cardiology, the Third Affiliated Hospital, SUN Yat-sun University, Guangzhou 510630, China Email: lj.lai@medmail.com.cn...
The paper described simply the PARADIGM-HF (prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in HF trial), and the results showed that comparing with the enalapril group, LCZ696(ARNI) reduced significantly primary endpoint (cardiovascular death or ...
2. 李小荣, 郑旭辉, 李新立. 血管紧张素受体脑啡肽酶抑制剂在心力衰竭治疗中的研究进展及展望. 中国循环杂志. 2018; 33-2. 3. Mann DL, Greene SJ, Givertz MM. Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. JACC Heart Fail. ...
3. Mann DL, Greene SJ, Givertz MM. Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial. JACC Heart Fail. 2020 Oct; 8(10): 789-799.
Efficacy of Sacubitril/ValsartanRelative to a Prior Decompensation in Patients with Heart Failure and ReducedEjection Fraction: The PARADIGM-HF Trial [manuscript]. American College of Cardiology’s65th Annual Scientific Session & Expo; Chicago, IL, USA. 2. McMurray JJV. Consistent Benefit OfSa...
西班牙巴塞罗那召开的欧洲心脏病学会(ESC)年会2014年8月30日正式公布了PARADIGMHF试验的结果,研究全文也在同日发表于《新英格兰医学杂志》。PARADIGM-HF试验全称prospec tive comparison of ARNI with ACEI to determine impact on global mortality and morbidity in heart failure trial,对比了血管紧张素受体...
PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure? 摘要: E Kaplinsky - 《Journal of Geriatric Cardiology》 被引量: 13发表: 2015年 PARADIGM-HF研究结果解读 心力衰竭的药物治疗虽然取得很多进展,但慢性心力衰竭患者5年死亡率却与恶性肿瘤相似,寻求新的治疗手段已成必需....
The trial enrolled 8,442 patients with NYHA class II, III or IV HF and an ejection fraction ≤40% who were randomly assigned to receive LCZ696 400 mg daily orenalapril20 mg daily in addition to standard care. The mean age of the patients was 63.8 years, one-...
PARADIGM-HF Trial and its Important Clinical Meanings 来自 Semantic Scholar 喜欢 0 阅读量: 26 作者: J Lai Liu 摘要: ACEI/ARB and β blocker and aldosterone antagonist have been a gold standard for treating chronic heart failure with reduced ejection fraction(EFr HF). The paper described simply...